I'm a physician with an interest in building a portfolio for total return. I subscribe to Ben Graham's value investing ethic, and am most interested in finding long-term investments trading at significant discounts to fair value.
After obtaining a BA in History (From my beloved Rutgers University) and a JD in Law, I've had several disparate careers including Artist Management, Music Production and as a Regional Partner Manager with four tech companies. I also server as a Registered Bond trader and Precious Metals Trader. I have traveled extensively around the world especially in Latin America and currently reside In Colombia South America, in the lovely City of Medellin. I trade for my own account.
On my own time I study natural approaches to health care and am writing a book and blogs concerning both the economics of marriage and mating in the global economy and various natural health issues and developments.
Private investment analyst and writer with an interest in companies with emerging technologies oriented towards improving healthcare, alternative investments, emerging markets, and technology.
I'm a chihuahua -- a VERY well trained one, I might add. Since my master handles all the bills, I could care less about investments. Nevertheless, I often find myself with a quite a bit of spare time on my paws and, given the dearth of toys that "fit" me, I turned instead to research of a condition that occasionally seems to affect my master -- "Bagholders Affective Syndrome." Seekingalpha is a positive goldmine of data for me! If I can find a cure, no doubt a Nobel will be waiting with my name on it! Of course, I'm presuming the Nobel committee hasn't anything against chihuahuas.
The Clinically Sound Investor is a pharmacist for a large retail corporation, with a PharmD and a BA in psychology. Fascinated by watching the rise of Walmart and Apple after 2008, he now follows the advice "know thyself" and puts expertise of understaning scientific literature to research biotechnology stocks. His investments early on were driven by binary events such as FDA Advisory Committee meetings and PDUFA dates (approvals). Despite initial successes, there were too few of these events, so he expanded into predicting Phase II/III trial results.
His writings should not be considered financial advice or the basis for investment decisions. While his interpretations of clinical trial results--which may be overlooked or even thoroughly misunderstood by Wall Street--could be helpful, they're only as good as the original reports they come from. Although written by scientists and doctors, there will always be a slant from the sponsoring company, or worse (like, say, missing data...).
10 years experience as a petroleum engineer In Texas, Louisiana, Mississippi, Saudi Arabia and Abu Dhabi. Education: Geology, Engineering and Accounting. 25 years as a public accountant in Corp acctg, tax and real estate. Red neck. Former Marine. World traveler and lap dance judge.
Spencer Osborne is founder of Satellite Standard Group [SSG], and a partner of Sirius Buzz (http://siriusbuzz.com/). Sirius Buzz covers the satellite radio industry as well as companies that do business in this sector. Sirius Buzz provides information and opinion to readers with an interest in the sector from an investment, as well as consumer perspective.
Along with his work in the media sector, Spencer covers various equities that interest him and writes about these equities from a unique and "out of the box" perspective. Over the years Spencer has built a network of resources within the sectors he writes about. His opinion and insight is oft referred to and sought after by analysts.
I have a BSEE, MSEE/CS and MBA in Finance and Marketing. I have been a successful sales and marketing executive for the last 16 years of my 37+ years in Engineering and Sales and Marketing working for excellent companies like HP, Intel, Anthem Electronics and Memec/Insight Electronics.
I trade mainly on sentiment & leave the more technical aspects to other Wolves, but I do chart. I have a group of traders that pool resources & $$$ to make the #Wolf-Fund. My persona on twitter @wolfofweedstreet only discusses Marijuana related stocks.
I Am the Wolf of Weed Street and while I love profits, I hate scammy companies that trade on over hyped pr's 3x a week and Unicorn farts. I am here to bring balance to the #MMJ universe...But always do your own DD and invest wisely.
Alan Brochstein, CFA, was the first investment professional to devote himself to sharing his observations about the cannabis industry from an investor's perspective publicly. He runs 420 Investor, a subscription-based due diligence platform for investors interested in the publicly-traded cannabis stocks and is also the founder of New Cannabis Ventures, a content aggregation site focused on investors and entrepreneurs in the cannabis industry.
Alan has worked in the securities industry since 1986, primarily with the responsibility for managing investments in institutional environments until he founded AB Analytical Services in 2007 in order to provide independent research and consulting to registered investment advisors. In addition to advising several different hedge funds and investment managers, including Friedberg Investment Management, where he participated as a member of its investment management committee, Alan was also a senior analyst for the independent research firm Management CV. In 2008, he began providing a first-of-its-kind subscription-based service for individual investors, Invest By Model, which offered two different portfolios that investors could replicate in their own accounts for $20 per month. Alan also offered The Analytical Trader at Marketfy, where he used fundamental and technical analysis in a disciplined process to offer specific trade ideas geared towards swing traders.
Alan launched www.420Investor.com in late 2013 as the premier source of information for "Green Rush" investors seeking to capitalize on the proliferation of legalized medical and recreational cannabis. In March 2014, Alan, who is a member of the National Cannabis Industry Association, began to focus solely on the cannabis sector. He launched www.NewCannabisVentures.com in late 2015.
You can follow Alan on Facebook (www.facebook.com/420investor) or on Twitter (https://twitter.com/Invest420). Alan also moderates a large LinkedIn group focused on the cannabis industry, Cannabis Investors & Entrepreneurs (https://www.linkedin.com/groups/6523904)
I worked in New York's financial sector for almost exactly 20 years, mostly as a healthcare analyst (drugs, biotech, and medical devices), but also as an assistant research director, portfolio manager, and options strategist. My last formal job had me in charge of Value Line's premium priced "Select" and "Special Situation" products. The former highlights the company's top stock pick of each month and the latter introduces relatively small companies. I quit that job in June, 2009 for reasons that a dozen or so confidentiality agreements preclude my discussing. In September of that year, I launched 3DimensionalResearch.com (3DR), which allows me to continue doing what I was doing previously.
I am a strong believer in maximum transparency, in both personal and business relationships. So, in that vein:
A google search will show that my former employer sued 3DR and me in November, 2009 for copyright infringement, hot news misappropriations, and the proverbial kitchen sink. Although a search won't show this, unfortunately, I represented myself in a federal courtroom in December and, in accordance with the judge's instructions, the case was settled in a matter of minutes.
Additional Disclosure: 3DR has been a financial failure thus far, in terms of getting subscribers. I detest marketing and few people want to pay for information anymore, least of all from a no-name website. That said, the vast majority of my recommendations have done very well and my personal portfolio is doing extraordinarily well (65.5% in 2013) since I tend to follow most of my own recommendations, the "event driven special situations," in particular.